Cancer Biopsy Market Size & Share 2024 to 2032

Cancer Biopsy Market Size

Cancer Biopsy Market size was valued at USD 21.5 billion in 2023 and is estimated to grow at a CAGR of 8.4% from 2024 to 2032. The market has witnessed significant growth driven by the increasing prevalence of cancer and advancements in cancer diagnostic technologies, including biopsies.

Innovative techniques such as liquid biopsy and next-generation sequencing (NGS) have attracted attention due to their high precision and minimally invasive nature. These technological advancements in cancer biopsy procedures are transforming cancer diagnostics by providing less invasive and more accurate methods for detecting and monitoring the disease. For instance, in 2019, the National Cancer Institute (NCI) reported that liquid biopsies can identify genetic mutations in over 70% of advanced cancer cases. This result aimed to enhance early detection, support personalized treatment strategies, and improve patient outcomes.
 

Furthermore, the increasing awareness of inherited oncology disorders and genetic testing is further driving demand. These technologies enable early detection and personalized treatment, resulting in improved patient outcomes. This has led to a growing emphasis on targeted cancer therapies that leverage insights gained from advanced biopsy techniques for diagnosis.
 

A cancer biopsy is a medical procedure that involves obtaining a tissue or cell sample from a suspicious area in the body to determine the presence of cancer. This process includes various methods such as needle biopsies, surgical biopsies, and liquid biopsies. The market encompasses both products, such as biopsy instruments and kits, and services, including diagnostic testing and analysis.
 

Cancer Biopsy Market Trends

The rising prevalence of cancer significantly drives the market, as increased cancer cases heighten the demand for precise diagnostic tools. This surge in cancer incidence leads to a growing need for various biopsy techniques for early and accurate detection and treatment planning.
 

• For instance, according to the International Agency for Research on Cancer (IARC) 2022 report, among 20 million new cancer cases worldwide, lung cancer and female breast cancer are the most common, representing 12.4% and 11.6% of cases, respectively. They are followed by colorectal cancer (9.6%), prostate cancer (7.3%), and stomach cancer (4.9%). This increasing incidence represents a large potential patient population requiring biopsies for diagnosis and treatment, bolstering market demand. This leads to greater adoption of various biopsy techniques, such as fine needle aspiration (FNA) and core needle biopsy (CNB), driving market growth.
   
• Additionally, the need for ongoing monitoring and assessment in cancer patients further expands the market, as repeat biopsies become essential for effective treatment management.
   

Cancer Biopsy Market Analysis

Based on biopsy type, the cancer biopsy market is segmented into tissue biopsy, liquid biopsy, image-guided biopsy and other biopsy types. The tissue biopsy segment dominates the market and is anticipated to grow at 8.3% CAGR over the forecast period. The tissue biopsy segment is further categorized into needle biopsy, surgical biopsy, and other tissue biopsy types.
 

• The segment's dominance is attributed primarily to its preference as the gold standard for cancer diagnosis, providing highly accurate and reliable results.
   
• Tissue biopsies offer comprehensive histological and molecular information, enabling accurate tumor characterization, which is essential for determining appropriate treatment strategies. The method's reliability in diagnosing various cancers, including breast, lung, and prostate cancers, contributes to its widespread adoption.
   
• Additionally, advancements in minimally invasive techniques and imaging technologies have enhanced the precision and safety of tissue biopsies, further solidifying their dominance.

Learn more about the key segments shaping this market

Download Free PDF

Based on the products and services, the cancer biopsy market is categorized into products and services The product segment accounted for highest market share of 65.5% in 2023 The product segment further bifurcated into biopsy needle/guns, biopsy forceps, kits and reagents, and consumables.
 

• The dominance of this segment is driven by advancements in biopsy technology, which improve accuracy and patient outcomes. Additionally, the rise in global cancer cases has led to higher demand for these products, as early detection and accurate diagnosis are critical for effective treatment.
   
• Furthermore, the ongoing development and enhancement of biopsy products, backed by extensive research and clinical validation, have significantly increased their adoption in the market. For instance, in 2023, the NCI highlighted that the continuous refinement of biopsy products led to a 20% increase in adoption rates among healthcare providers from 2020 to 2023, driven by the positive impact of new innovations on patient care and diagnostic precision.
   
• These factors collectively drive the growth of the biopsy product segment in the market, underscoring its vital role in the accurate and effective diagnosis of cancer.
   

Based on cancer type, the cancer biopsy market is segmented into breast, colorectal, stomach, lung, liver, prostrate, ovarian, and other cancer types. The breast cancer segment is poised to reach USD 8.7 billion by 2032.
 

• The increasing incidence of breast cancer worldwide has driven the demand for biopsies, making them an essential component of breast cancer management. For instance, according to the NCI, the incidence rate of breast cancer increased by approximately 0.5% per year between 2013 and 2018. In 2023, the estimated number of new breast cancer cases was around 297,790. This rising prevalence underscores the urgent need for continuous advancements in early detection, diagnosis, and treatment strategies, thereby propelling the demand for biopsy procedures.
   
• Additionally, the development of advanced biopsy techniques, supported by robust research and clinical evidence, has further bolstered the demand within this segment.
   
• These factors collectively drive the growth of the breast cancer segment in the market, highlighting its pivotal role in addressing the increasing burden of breast cancer globally.
   

Based on end-user, the cancer biopsy market is segmented into hospitals, cancer research centers, diagnostic centers, and research and academics. The hospital segment dominated the market accounting for USD 10.4 billion in 2023.
 

• Hospitals' dominance is due to their extensive diagnostic capabilities and access to cutting-edge medical technologies. Equipped with advanced imaging and biopsy tools, they facilitate accurate and efficient cancer diagnosis.
   
• Their ability to perform complex biopsies, such as image-guided and surgical biopsies, within a hospital setting enhances patient trust and drives the preference for hospitals over other healthcare providers.
   
• Additionally, hospitals often serve as primary care centers for cancer patients, further solidifying their leading position in the market.

U.S. cancer biopsy market size accounted for USD 8.9 billion in 2023 and is anticipated to reach USD 18 billion by 2032.
 

• The U.S. prominence in the North American market is due to advanced healthcare infrastructure, significant investment in research and development, and the presence of leading medical device companies.
   
• The country’s robust focus on early cancer detection and personalized medicine, coupled with widespread adoption of innovative biopsy technologies, contributes to its dominance.
   
• Additionally, strong governmental support, a high incidence of cancer, and extensive clinical trials further enhance the U.S.'s leadership in the region, making it a key player in the North American market.
   
• For instance, according to the American Cancer Society, approximately 1.9 million new cancer cases are expected in 2024, highlighting the increasing need for advanced diagnostic tools. Thus, the growing demand for innovative diagnostic tools and techniques continues to solidify the U.S.'s leadership in the region.
   

The Asia Pacific cancer biopsy market is poised for rapid growth with a CAGR of 8.7% during the forecast period.
 

• The growing awareness and utilization of genetic testing in the Asia Pacific region emphasize the crucial need for early and accurate cancer detection. This trend has increased the demand for advanced biopsy techniques providing precise diagnoses and effective treatment strategies.
   
• Furthermore, the advancement and enhanced accessibility of innovative biopsy technologies in the region, supported by government initiatives and healthcare investments, have significantly contributed to market growth.
   

Cancer Biopsy Market Share

The market is characterized by intense competition among major players focusing on advancements in diagnostic technologies and innovative biopsy solutions. Key strategies include significant investment in research and development to enhance the accuracy and effectiveness of biopsy techniques, strategic partnerships and acquisitions to expand market reach, and collaborations with healthcare providers and research institutions to drive technological innovations and improve patient outcomes.
 

Cancer Biopsy Market Companies

Few of the prominent players operating in the cancer biopsy industry include:

• ANGLE plc
• BD (Becton, Dickinson and Company)
• Biodesix (Integrated Diagnostics)
• Chronix Biomedical, Inc (Oncocyte Corporation )
• Devicor Medical Products, Inc.
• GRAIL, Inc.
• Hologic, Inc.
• Illumina, Inc.
• IZI Medical Products 
• Lucence Health Inc.
• Myriad Genetics, Inc.
• Oncimmune Holdings PLC
• Personal Genome Diagnostics Inc.
• QIAGEN N.V.
   

Cancer Biopsy Industry News:

• In April 2024, QIAGEN N.V. launched a new product line, including the QIAcuity dPCR PanCancer kits, designed to advance cancer research. Additionally, the company introduced a novel approach for liquid biopsy with products enabling urine collection and stabilization. This development represented significant advancements in cancer research, enhancing diagnostic precision and research capabilities.
   
• In August 2022, Guardant Health received U.S. FDA approval for its Guardant360 companion diagnostics (CDx) liquid biopsy test to identify advanced or metastatic breast cancer. This approval marked a significant advancement as the test became a CDx for selecting patients with unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC).
   

The cancer biopsy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Biopsy Type

• Tissue biopsy
  • Needle biopsy
  • Surgical biopsy
  • Other tissue biopsy types    
• Liquid biopsy
  • Circulating tumor cells (CTCs)      
  • Circulating tumor DNA (ctDNA)    
  • Other liquid biopsy types
• Image-guided biopsy
• Other biopsy types

Market, By Products & Services

• Products
  • Biopsy needles/guns
    • Fine needle aspiration (FNA)
    • Core needle biopsy (CNB)
    • Vacuum-assisted biopsy devices
  • Biopsy forceps
    • General biopsy forceps      
    • Hot biopsy forceps  
  • Kits and reagents
  • Consumables 
• Services

Market, By Cancer Type

• Breast cancer
• Colorectal cancer
• Stomach cancer
• Lung cancer
• Liver cancer
• Prostate cancer
• Ovarian cancer
• Other cancer types

Market, By End-user

• Hospitals
• Cancer research centers
• Diagnostic centers
• Research and academics

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa